Pathogenesis of myeloma bone disease

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Multiple myeloma (MM) is the most common cancer to involve bone with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and will be discussed in this chapter.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalJournal of Cellular Biochemistry
Volume109
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Bone Diseases
Bone
Bone and Bones
Multiple Myeloma
Neoplasm Metastasis
Tumors
Neoplasms
Spontaneous Fractures
Bone Resorption
Tumor Burden
Osteoblasts
Osteogenesis

Keywords

  • Bone disease
  • Metastasis
  • Myeloma

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Pathogenesis of myeloma bone disease. / Roodman, G. David.

In: Journal of Cellular Biochemistry, Vol. 109, No. 2, 01.02.2010, p. 283-291.

Research output: Contribution to journalArticle

@article{8918409720ab4dad9f408c2d52cd18d7,
title = "Pathogenesis of myeloma bone disease",
abstract = "Multiple myeloma (MM) is the most common cancer to involve bone with up to 90{\%} of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60{\%} of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50{\%} in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and will be discussed in this chapter.",
keywords = "Bone disease, Metastasis, Myeloma",
author = "Roodman, {G. David}",
year = "2010",
month = "2",
day = "1",
doi = "10.1002/jcb.22403",
language = "English (US)",
volume = "109",
pages = "283--291",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Pathogenesis of myeloma bone disease

AU - Roodman, G. David

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Multiple myeloma (MM) is the most common cancer to involve bone with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and will be discussed in this chapter.

AB - Multiple myeloma (MM) is the most common cancer to involve bone with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and will be discussed in this chapter.

KW - Bone disease

KW - Metastasis

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=74949100969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949100969&partnerID=8YFLogxK

U2 - 10.1002/jcb.22403

DO - 10.1002/jcb.22403

M3 - Article

C2 - 20014067

AN - SCOPUS:74949100969

VL - 109

SP - 283

EP - 291

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 2

ER -